BioTuesdays

Category - Developments

Ocular Therapeutix

Ocular, Regeneron in wet AMD collaboration

Ocular Therapeutix (NASDAQ:OCUL) has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (NASDAQ:REGN) to develop a sustained release formulation of the vascular...

Mateon Therapeutics

Mateon gets U.S. patent for cathepsin inhibition

The U.S. Patent and Trademark Office has issued a patent to Mateon Therapeutics (NASDAQ:MATN) and Baylor University that covers compounds which modulate cathepsin activity, particularly cathepsin L or cathepsin K, and...

Mesoblast Logo

Mesoblast diabetic kidney disease data published

Results of Mesoblast’s (NASDAQ:MESO; ASX:MSB) Phase 2 trial of its allogeneic mesenchymal precursor cell (MPC) product candidate, MPC-300-IV, in patients with diabetic kidney disease have been published in the current...

Dipexium Pharmaceuticals

Dipexium gets SME designation in Europe

Dipexium Pharmaceuticals (NASDAQ:DPRX) has been granted small and medium enterprise (SME) designation by the European Medicines Agency (EMA).  The company recently completed its pivotal Phase 3 clinical trials...